Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Intercept Pharmaceuticals Inc's liver disease drug meets main goal in study - Reuters


Thursday, 9 Jan 2014 08:07am EST 

Intercept Pharmaceuticals Inc:Says an analysis by an independent safety committee showed that its liver disease drug met the main goal of a mid-stage trial - Reuters.Says it had stopped the trial after the committee found that the drug, obeticholic acid, showed statistically significant improvement in patients, compared with a placebo.Says the committee made the recommendation after reviewing liver biopsy data from about half of the 283 patients enrolled in the trial.Says the trial tested the drug in patients with non-alcoholic steatohepatitis, a form of liver inflammation caused by a build-up of fat. 

Company Quote

222.2
-1.2 -0.54%
11 Jul 2014